{"id":"W4399458651","doi":"10.1016/j.ejca.2024.114145","title":"Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer","year":2024,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"SickKids Foundation","funders":"National Cancer Institute; Loxo Oncology; Norgine; EUSA Pharma; Y-mAbs Therapeutics; Solving Kids' Cancer; Rally Foundation; Amgen; Eli Lilly and Company; Pediatric Brain Tumor Foundation","keywords":"PI3K/AKT/mTOR pathway; Discovery and development of mTOR inhibitors; Protein kinase B; Cancer; Product (mathematics); Medicine; Cancer research; Internal medicine; Chemistry; Phosphorylation; Signal transduction; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006917018,0.000388839,0.0008146854,0.0002192618,0.00003839617,0.00003063976,0.0002482348,0.00008601466,0.000006175288],"category_scores_gemma":[0.00003376726,0.0002667886,0.0001364662,0.0001927707,0.0001139554,0.000009650906,0.0001136124,0.0003731843,4.899242e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001046614,"about_ca_system_score_gemma":0.001382613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001654474,"about_ca_topic_score_gemma":0.00007283082,"domain_scores_codex":[0.9979225,0.0001540251,0.0009017458,0.000439217,0.0002902544,0.0002921951],"domain_scores_gemma":[0.9986845,0.000009115913,0.0008139026,0.0001597963,0.0001942982,0.0001384447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001293914,0.00003799652,0.003378364,0.004771278,0.0004740203,0.00001676052,0.00008015891,0.0000171567,0.0002105661,7.538679e-7,0.002921503,0.9879621],"study_design_scores_gemma":[0.00199269,0.001208206,0.002705222,0.03547797,0.001536338,0.0002386365,0.00003638073,0.000001102733,0.001124542,0.000003203068,0.9550254,0.0006502514],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01022599,0.9885907,0.00004893617,0.00004316713,0.0004622951,0.0005157889,0.00008124396,0.000003062994,0.00002886866],"genre_scores_gemma":[0.04527455,0.9525138,0.0003059866,0.00003442538,0.001621932,0.0000299677,0.00001757741,0.0001040746,0.0000976482],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9873118,"threshold_uncertainty_score":0.9999784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01731181423656138,"score_gpt":0.3037225914434496,"score_spread":0.2864107772068882,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}